Skip header and navigation

1 records – page 1 of 1.

A cost effective approach to surgical antibiotic prophylaxis.

https://arctichealth.org/en/permalink/ahliterature223292
Source
Can J Hosp Pharm. 1992 Aug;45(4):151-6
Publication Type
Article
Date
Aug-1992
Author
M M Pavan
D L Malyuk
Author Affiliation
Royal Columbian Hospital, New Westminster, British Columbia.
Source
Can J Hosp Pharm. 1992 Aug;45(4):151-6
Date
Aug-1992
Language
English
Publication Type
Article
Keywords
Appendectomy - adverse effects - economics
British Columbia
Cefazolin - economics - therapeutic use
Cefoxitin - economics - therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination - economics - therapeutic use
Evaluation Studies as Topic
Hospital Bed Capacity, 500 and over
Humans
Interdepartmental Relations
Metronidazole - economics - therapeutic use
Pharmacy Service, Hospital - economics - statistics & numerical data
Premedication - economics
Questionnaires
Random Allocation
Research Design
Surgical Wound Infection - economics - prevention & control
Abstract
Cefoxitin has been the prophylactic antibiotic of choice for appendectomy and colorectal surgery at this institution. Recent information suggests that cefazolin and metronidazole given as a single intravenous preparation could be a cost-effective alternative to cefoxitin or cefotetan for surgical antimicrobial prophylaxis of uncomplicated appendectomies. This study was conducted to determine the efficacy, toxicity, and cost of the current antibiotic regimens used for prophylaxis of uncomplicated appendectomies, to evaluate the efficacy, toxicity and cost of the cefazolin plus metronidazole combination in uncomplicated appendectomies, and to facilitate a cooperative working relationship between the Departments of Pharmacy and General Surgery. Although the numbers involved were small, this study suggests that the cefazolin/metronidazole combination is cost-effective. It is suggested that research is warranted in evaluating combinations such as this as cost-effective alternatives to current therapy.
PubMed ID
10123058 View in PubMed
Less detail